PwPepwise

GHRP-6

Growth Hormone

Ghrelin receptor agonist

GHRP-6 (Growth Hormone-Releasing Peptide-6) is a synthetic six-amino-acid peptide that stimulates the body's natural release of growth hormone (GH).

§Dosing at a glance

4 protocols · from the research
What it's forDoseHow oftenHowFor how long
GH Stimulation / Diagnostic Testing (Human, IV)1 mcg/kg—IntravenousInjected directly into a vein.—
Repetitive Nocturnal Dosing (Human, IV)50 mcg———
Gastroprokinetic Applications (Animal, IP)10–150 mcg/kg—IntraperitonealInjected into the abdominal cavity (research use).—
into the nose Administration (Animal)5 mg/kg—IntranasalSprayed into the nose.—

Approximate values pulled from the research — double-check before dosing.

§01Summary

GHRP-6 (Growth Hormone-Releasing Peptide-6) is a synthetic six-amino-acid peptide that stimulates the body's natural release of growth hormone (GH) by activating a specific receptor — now known as the ghrelin receptor — found in the brain and pituitary gland. It works through pathways distinct from, but complementary to, the body's own growth hormone-releasing hormone (GHRH), and the two signals together produce a powerfully amplified GH response10. In clinical research, GHRP-6 has been reported to robustly elevate GH levels in both healthy adults and individuals with blunted GH secretion, such as those with obesity10 or traumatic brain injury7. The combined GHRH+GHRP-6 stimulation test has been evaluated as a diagnostic tool for identifying GH deficiency in adults, demonstrating strong discriminatory power with a favorable safety profile compared to traditional testing methods3. Beyond GH release, GHRP-6 may also influence appetite, sleep architecture, and gastrointestinal motility2,5,8. It has been reported to stimulate ACTH and cortisol secretion and to enhance stage 2 sleep duration2. Research into novel applications — including cardiovascular and metabolic indications — is actively developing, with early preclinical findings supporting a broader biological role for this compound and its derivatives17.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂) is a synthetic hexapeptide GH secretagogue that acts as an agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a), a seven-transmembrane G protein-coupled receptor (GPCR) that is highly expressed in the pituitary and hypothalamus and was subsequently identified as the cognate receptor for the endogenous orexigenic hormone ghrelin4,20. The receptor shares greater than 90% sequence identity across rat, human, and swine species, contains a single intron dividing its open reading frame into two exons, and binds GHRP-6 and related peptidomimetics with high affinity (Kd ~0.7 nM for the radiolabeled analog MK-0677)20.

At the intracellular signaling level, GHS-R1a activation by GHRP-6 couples primarily to the phospholipase C/inositol trisphosphate (IP3) pathway, elevating intracellular calcium and activating protein kinase C (PKC)4,11. Crucially, GHRP-6 does not independently activate adenylyl cyclase or elevate cAMP, yet potentiates GHRH-stimulated cAMP accumulation through PKC-mediated cross-talk between these two second messenger cascades6,11. PKC inhibition or depletion markedly attenuates but does not fully abolish GHRP-6-induced GH release, indicating that additional intracellular pathways are simultaneously engaged11.

GHRP-6 operates at both pituitary and hypothalamic levels to amplify pulsatile GH secretion. At the hypothalamus, GHS-R1a is expressed on GHRH-containing neurons in the arcuate and ventromedial nuclei15, and GHRP-6 activates these neurons directly — as evidenced by dense c-Fos expression in the ventral arcuate nucleus following intracerebroventricular administration, a pattern not reproduced by GHRH13. In vivo, passive immunoneutralization against endogenous GHRH virtually abolishes GH responses to GHRP-6 in rodents15, and pharmacological GHRH receptor blockade in humans reduces the GH response to GHRP-6 by approximately 78–82%, with a residual ~18–22% response persisting1. This residual response likely reflects direct pituitary GHS-R1a activation or modulation of somatostatinergic tone independent of the GHRH axis1. The synergy between GHRP-6 and GHRH exceeds simple additivity — combined administration produces supra-additive GH responses that are partially resistant to somatostatin inhibition, whereas either agent alone is fully suppressible by somatostatin12.

Beyond the somatotropic axis, GHRP-6 activates the hypothalamic-pituitary-adrenal axis, significantly elevating ACTH and cortisol2, and engages appetite-regulating circuits by activating arcuate nucleus AgRP/NPY neurons and orexin-containing (but not MCH-containing) lateral hypothalamic neurons, with orexigenic effects mediated through NPY Y1 receptor signaling5,16. In the gastrointestinal tract, GHS-R1a activation by GHRP-6 accelerates gastric emptying and enhances intestinal transit via enteric cholinergic and nitrergic pathways, with efficacy exhibiting a bell-shaped dose-response curve in some animal models8,9. GHRP-6 also desensitizes its own receptor rapidly and reversibly (approximately 60-minute recovery), without cross-desensitization to GHRH receptors, an important pharmacological property for therapeutic dosing interval design6,12.

§04Evidence & efficacy

Evidence base
198Studies
45Human
95Animal

GHRP-6 demonstrates robust GH-releasing activity in humans across multiple controlled studies. Intravenous administration at 1 mcg/kg produces a peak GH response of approximately 33.8 mcg/L under control conditions1, and the combined GHRH+GHRP-6 protocol generates mean peak GH values of 59.2 mcg/L in healthy adults compared to 4.1 mcg/L in GH-deficient patients3. In obese individuals — who typically exhibit blunted GH secretion — the GHRP-6+GHRH combination produces synergistic GH discharge with mean peaks of 42.2 mcg/L (range 14–86 mcg/L), far exceeding responses achievable with either agent alone10. Further suppression of plasma free fatty acids in obese subjects may enhance this response even further, with GHRH+GHRP-6 AUC increasing approximately 49% following acipimox pretreatment14.

The GHRH+GHRP-6 stimulation test has been evaluated as a diagnostic tool for adult GH deficiency, with a proposed discriminatory cut-off of 15 mcg/L showing strong separation between controls and GH-deficient patients on ROC analysis, and appearing robust across age, sex, adiposity, and assay type3.

GHRP-6 may also stimulate ACTH and cortisol secretion and appears to enhance stage 2 sleep duration when administered nocturnally2. In rodent models, GHRP-6 accelerates gastric emptying and intestinal transit via enteric cholinergic pathways8,9, and centrally administered GHRP-6 may stimulate food intake through NPY/Y1 and orexin signaling in appetite-regulating hypothalamic circuits5,16. Intranasal delivery of GHRP-6 has been reported to elevate both food intake and serum GH in mice16, suggesting potential for non-invasive administration routes that are currently being investigated.

Preclinical research further suggests that azapeptide derivatives of GHRP-6 targeting CD36 may have atheroprotective and atheroregressive properties in animal models of atherosclerosis17, representing an active area of translational development.

§05Safety

Across human studies conducted to date, GHRP-6 has demonstrated a favorable acute tolerability profile. In controlled clinical investigations — including intravenous bolus administration at 1 mcg/kg1, repetitive nocturnal IV dosing at 4 × 50 mcg2, and combined GHRH+GHRP-6 diagnostic testing3 — no significant adverse events were reported. The GHRH+GHRP-6 combination test was specifically noted to produce no side effects in participants, and its authors highlighted this as a safety advantage over the insulin tolerance test, which carries risks of insulin-induced hypoglycemia3.

A pharmacologically notable finding is that GHRP-6 robustly stimulates the hypothalamic-pituitary-adrenal (HPA) axis, significantly elevating both ACTH and cortisol levels during nighttime administration — an effect that directly contrasts with the cortisol-blunting profile of GHRH2. This HPA axis activation is a consistent and documented biological effect rather than an incidental finding, and its implications for chronic or repeated dosing are an area of ongoing research interest.

In animal studies, transient reductions in core body temperature were observed following central (intracerebroventricular) administration in rodents5,19, though this route is not used clinically. In vitro, receptor desensitization with a transient ~30% reduction in basal GH release was observed at high concentrations after prolonged exposure, though the effect was fully reversible within one hour6. No drug interactions or contraindications have been reported in the reviewed literature.

Long-term human safety data and data from therapeutic (as opposed to diagnostic or research) dosing regimens are emerging as active areas of clinical investigation.

§06History

GHRP-6 was developed from pioneering structure-activity studies on enkephalin analogs conducted by Cyril Bowers and colleagues beginning in the 1970s, who observed that certain opioid-related peptides possessed unexpected GH-releasing activity independent of opioid receptors. The specific hexapeptide sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂ was identified as a particularly potent and selective GH secretagogue and became a key research tool6. Early foundational work in the late 1980s and early 1990s established that GHRP-6 acts through a receptor and signaling pathway entirely distinct from GHRH — operating via phospholipase C/PKC rather than adenylyl cyclase/cAMP — and that it synergizes powerfully with GHRH to amplify GH secretion6,11,12.

The 1990s saw GHRP-6 transition into human clinical research, with studies characterizing its GH-releasing, HPA-stimulating, and sleep-modifying effects1,2,10. A landmark 1997 review described the medicinal chemistry evolution from GHRP-6 toward orally bioavailable peptidomimetics such as MK-0677, culminating in the identification and cloning of the GHS-R1a receptor4,20. The discovery of ghrelin in 1999 as the endogenous GHS-R1a ligand — a milestone foreshadowed by the receptor cloning work20 — fundamentally contextualized GHRP-6 within a broader endocrine regulatory system governing energy homeostasis and GH pulsatility5.

The GHRH+GHRP-6 combination was subsequently validated as a potent and safe GH provocative test for diagnosing adult GH deficiency, published in The Lancet in 20003. Contemporary research continues to explore GHRP-6 derivatives for cardiovascular17, metabolic, and non-invasive delivery applications16, representing an actively expanding translational landscape.

§07References